Femasys Inc. (NASDAQ:FEMY) Short Interest Up 24.3% in September

Femasys Inc. (NASDAQ:FEMY) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 684,700 shares, an increase of 24.3% from the August 31st total of 550,800 shares. Currently, 3.3% of the company’s stock are short sold. Based on an average daily trading volume, of 141,200 shares, the days-to-cover ratio is presently 4.8 days.

Hedge Funds Weigh In On Femasys

An institutional investor recently raised its position in Femasys stock. Clear Creek Financial Management LLC grew its position in Femasys Inc. (NASDAQ:FEMY) by 30.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 309,274 shares of the company’s stock after acquiring an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned about 1.40% of Femasys worth $479,000 at the end of the most recent quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Femasys in a research report on Thursday, September 12th. Chardan Capital cut their price objective on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Femasys Price Performance

NASDAQ:FEMY opened at $1.12 on Monday. Femasys has a 52-week low of $0.73 and a 52-week high of $4.75. The company has a market cap of $24.89 million, a P/E ratio of -1.33 and a beta of -2.81. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 6.47. The stock’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.23.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Femasys had a negative net margin of 1,757.16% and a negative return on equity of 119.97%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, sell-side analysts forecast that Femasys will post -0.79 EPS for the current fiscal year.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.